AR090994A1 - BICYCLICALLY REPLACED URACILES AND USE OF THE SAME - Google Patents

BICYCLICALLY REPLACED URACILES AND USE OF THE SAME

Info

Publication number
AR090994A1
AR090994A1 ARP130101600A ARP130101600A AR090994A1 AR 090994 A1 AR090994 A1 AR 090994A1 AR P130101600 A ARP130101600 A AR P130101600A AR P130101600 A ARP130101600 A AR P130101600A AR 090994 A1 AR090994 A1 AR 090994A1
Authority
AR
Argentina
Prior art keywords
alkyl
hydrogen
halogen
difluoromethyl
trifluoromethyl
Prior art date
Application number
ARP130101600A
Other languages
Spanish (es)
Inventor
Dr Frstner Chantal
Dr Ackerstaff Jens
Dr Straub Alexander
Dr Meier Heinrich
Dr Zimmermann Katja
Dr Tersteegen Adrian
Dr Schamberger Jens
Dr Tinel Hanna
Dr Brngen Kirsten
Dr Zubov Dmitry
Dr Kast Raimund
Dr Schfer Martina
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of AR090994A1 publication Critical patent/AR090994A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/5381,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Abstract

La presente solicitud se refiere a derivados de uracilo sustituidos bicíclicamente, a procedimientos de preparación de los mismos, al uso de los mismos solos o en combinaciones para el tratamiento y/o la prevención de enfermedades y al uso de los mismos para la producción de medicamentos para el tratamiento y/o la prevención de enfermedades. Reivindicación 1: Compuesto de la fórmula (1) en la que R¹ es hidrógeno o alquilo C₁₋₄; R² es un grupo de la fórmula (2), (3) ó (4) en la que * es el sitio de unión al átomo de nitrógeno del uracilo; A es -CH₂-, -CH₂-CH₂-, -O-CH₂-## u oxígeno, en el que ## es el sitio de unión al anillo de fenilo; m es el número 0, 1 ó 2; R⁴ es halógeno, difluorometilo, trifluorometilo, alquilo C₁₋₄, difluorometoxi, trifluorometoxi o alcoxi C₁₋₄; R⁵A es hidrógeno o deuterio; R⁵B es hidrógeno, deuterio o alquilo C₁₋₄; R⁶ es hidrógeno o flúor; R⁷ es hidrógeno o flúor; R⁸ es halógeno, difluorometilo, trifluorometilo, alquilo C₁₋₄ o nitro; R⁹ es hidrógeno, halógeno, difluorometilo, trifluorometilo, alquilo C₁₋₄, nitro o alquil C₁₋₄-tio; R³ es un grupo de la fórmula (5) en la que # es el sitio de unión al átomo de nitrógeno del uracilo; el anillo Q es heterociclo de 5 a 7 miembros o heteroarilo de 5 ó 6 miembros, en el que el heterociclo de 5 a 7 miembros o el heteroarilo de 5 ó 6 miembros puede estar sustituido con 1 a 4 sustituyentes seleccionados independientemente del grupo de halógeno, difluorometilo, trifluorometilo, trideuterometilo, alquilo C₁₋₆, cicloalquilo C₃₋₇, oxo, hidroxilo, alquil C₁₋₄-carbonilo, alcoxi C₁₋₄-carbonilo, aminocarbonilo y alquil C₁₋₄-sulfonilo, en el que el alquilo C₁₋₆ y el cicloalquilo C₃₋₇, ₐ ₛᵘ ᵛₑᶻ, ₚᵘₑᵈₑₙ ₑₛₜₐʳ ₛᵘₛₜⁱₜᵘⁱᵈₒₛ ᶜₒₙ ₁ ₐ ₃ ₛᵘₛₜⁱₜᵘʸₑₙₜₑₛ ₛₑₗₑᶜᶜⁱₒₙₐᵈₒₛ ⁱₙᵈₑₚₑₙᵈⁱₑₙₜₑₘₑₙₜₑ ᵈₑₗ ᵍʳᵘₚₒ ᵈₑ ₕₐₗóᵍₑₙₒ, ᶜⁱₐₙₒ, ₜʳⁱᶠₗᵘₒʳₒₘₑₜⁱₗₒ, ᶜⁱᶜₗₒₐₗqᵘⁱₗₒ C₃₋₇, hidroxilo, alcoxi C₁₋₄ y heterociclo de 4 a 7 miembros, y en el que dos radicales alquilo C₁₋₆ unidos a un átomo de carbono del heterociclo de 5 a 7 miembros y el heteroarilo de 5 ó 6 miembros, junto con el átomo de carbono al que están unidos, pueden formar un carbociclo de 3 a 6 miembros; R²⁴ es halógeno, alquilo C₁₋₄ o alcoxi C₁₋₄; n es el número 0, 1, 2 ó 3; y las sales, solvatos y solvatos de las sales del mismo.The present application refers to bicyclic substituted uracil derivatives, their preparation procedures, their use alone or in combinations for the treatment and / or prevention of diseases and their use for the production of medicines. for the treatment and / or prevention of diseases. Claim 1: Compound of the formula (1) wherein R¹ is hydrogen or C₁₋₄ alkyl; R² is a group of the formula (2), (3) or (4) in which * is the binding site to the uracil nitrogen atom; A is -CH₂-, -CH₂-CH₂-, -O-CH₂ - ## or oxygen, in which ## is the phenyl ring binding site; m is the number 0, 1 or 2; R⁴ is halogen, difluoromethyl, trifluoromethyl, C₁₋₄ alkyl, difluoromethoxy, trifluoromethoxy or C₁₋₄ alkoxy; R⁵A is hydrogen or deuterium; R⁵B is hydrogen, deuterium or C₁₋₄ alkyl; R⁶ is hydrogen or fluorine; R⁷ is hydrogen or fluorine; R⁸ is halogen, difluoromethyl, trifluoromethyl, C₁₋₄ alkyl or nitro; R⁹ is hydrogen, halogen, difluoromethyl, trifluoromethyl, C₁₋₄ alkyl, nitro or C₁₋₄-thio alkyl; R³ is a group of the formula (5) in which # is the binding site to the uracil nitrogen atom; the Q ring is 5-7 membered heterocycle or 5-6 membered heteroaryl, in which the 5-7 membered heterocycle or the 5- or 6 membered heteroaryl can be substituted with 1 to 4 substituents independently selected from the halogen group , difluoromethyl, trifluoromethyl, trideuterometyl, C₁₋₆ alkyl, C₃₋₇ cycloalkyl, oxo, hydroxyl, C₁₋₄-alkylcarbonyl, C₁₋₄-carbonyl alkoxy, aminocarbonyl and C₁₋₄-sulfonyl alkyl, wherein the C₁ alkyl ₋₆ and the cycloalkyl C₃₋₇, ₐ ₛᵘ ᵛₑᶻ, ₚᵘₑᵈₑₙ ₑₛₜₐʳ ₛᵘₛₜⁱₜᵘⁱᵈₒₛ ᶜₒₙ ₁ ₐ ₃ ᵍʳᵘₚₒ ᵈₑ ₕₐₗóᵍₑₙₒ, ᶜⁱₐₙₒ, ₜʳⁱᶠₗᵘₒʳₒₘₑₜⁱₗₒ, ᶜⁱᶜₗₒₐₗqᵘⁱₗₒ C₃₋₇, hydroxyl, C alco alkoxy and heterocycle 4 to 7 members, and in which two C₁₋₆ alkyl radicals attached to a carbon atom of the 5-7 membered heterocycle and the 5 or 6 membered heteroaryl, together with the carbon atom to which they are attached, can form a 3 to 6 member carbocycle; R²⁴ is halogen, C₁₋₄ alkyl or C₁₋₄ alkoxy; n is the number 0, 1, 2 or 3; and the salts, solvates and solvates of the salts thereof.

ARP130101600A 2012-05-09 2013-05-08 BICYCLICALLY REPLACED URACILES AND USE OF THE SAME AR090994A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12167231 2012-05-09

Publications (1)

Publication Number Publication Date
AR090994A1 true AR090994A1 (en) 2014-12-30

Family

ID=48289199

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130101600A AR090994A1 (en) 2012-05-09 2013-05-08 BICYCLICALLY REPLACED URACILES AND USE OF THE SAME

Country Status (43)

Country Link
US (5) US9481672B2 (en)
EP (2) EP3045456B1 (en)
JP (2) JP6141414B2 (en)
KR (1) KR102083281B1 (en)
CN (2) CN104395310B (en)
AP (1) AP2014008096A0 (en)
AR (1) AR090994A1 (en)
AU (2) AU2013258223B2 (en)
CA (1) CA2872906C (en)
CL (1) CL2014003031A1 (en)
CO (1) CO7131375A2 (en)
CR (1) CR20140513A (en)
CU (1) CU20140129A7 (en)
CY (2) CY1118900T1 (en)
DK (2) DK2847190T3 (en)
DO (1) DOP2014000255A (en)
EA (2) EA031222B1 (en)
EC (1) ECSP14026138A (en)
ES (2) ES2657315T3 (en)
HK (1) HK1202873A1 (en)
HR (2) HRP20160796T1 (en)
HU (2) HUE029366T2 (en)
IL (2) IL235438A (en)
JO (1) JO3290B1 (en)
LT (1) LT3045456T (en)
MX (2) MX367599B (en)
MY (1) MY181828A (en)
NO (1) NO3045456T3 (en)
NZ (1) NZ701700A (en)
PE (1) PE20142301A1 (en)
PH (1) PH12014502496B1 (en)
PL (2) PL3045456T3 (en)
PT (2) PT2847190T (en)
RS (2) RS56784B1 (en)
SA (1) SA113340533B1 (en)
SG (1) SG10202003175QA (en)
SI (2) SI3045456T1 (en)
TN (1) TN2014000470A1 (en)
TW (2) TWI579278B (en)
UA (1) UA112897C2 (en)
UY (1) UY34797A (en)
WO (1) WO2013167495A1 (en)
ZA (1) ZA201408146B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA112897C2 (en) * 2012-05-09 2016-11-10 Байєр Фарма Акцієнгезелльшафт BICYCLIC SUBSTITUTED URATILES AND THEIR APPLICATIONS FOR THE TREATMENT AND / OR PREVENTION OF DISEASES
JP2016535095A (en) * 2013-11-08 2016-11-10 バイエル ファーマ アクチエンゲゼルシャフト Substituted 1,2,4-triazine-3,5-diones and their use as chymase inhibitors
LT3066097T (en) * 2013-11-08 2018-02-12 Bayer Pharma Aktiengesellschaft Salts of 1-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1r)-4-(trifluormethyl)-2,3-dihydro-1h-inden-1-yl]-1,2,3,4-tetrahydropyrimidin-5-carbonic acid
CN105873919A (en) * 2013-11-08 2016-08-17 拜耳医药股份有限公司 Substituted uracils as chymase inhibitors
EP3066098A1 (en) * 2013-11-08 2016-09-14 Bayer Pharma Aktiengesellschaft Substituted uracils and use thereof
WO2017162661A1 (en) 2016-03-22 2017-09-28 Bayer Pharma Aktiengesellschaft 1h-benzo[de]isoquinoline-1,3(2h)-diones
EP3338780A1 (en) * 2016-12-20 2018-06-27 Bayer Pharma Aktiengesellschaft Use of chymase inhibitors for the treatment of endometriosis, post-operative fibrosis and diseases characterized by the formation of fibrosis
CA3061444A1 (en) 2017-04-27 2018-11-01 Bayer Aktiengesellschaft Selective adrenoreceptor .alpha.2c receptor antagonists alone, or in combination with chymase inhibitors for use in the treatment and/or prophylaxis of peripheral artery diseases (pad)
JP2021523201A (en) 2018-05-15 2021-09-02 バイエル アクチェンゲゼルシャフトBayer Aktiengesellschaft 1,3-thiazole-2-yl-substituted benzamide for treating diseases associated with nerve fiber sensitization
CN110229067A (en) * 2019-06-05 2019-09-13 南京焕然生物科技有限公司 A kind of 2- amino indenes preparation method
WO2021000933A1 (en) * 2019-07-03 2021-01-07 南京明德新药研发有限公司 Pyrimidinone compounds as chymase inhibitors and application thereof
CN111440141A (en) * 2020-05-20 2020-07-24 安徽泽升科技有限公司 Preparation method of hydroxymethyl substituted aromatic heterocyclic compound
WO2022135514A1 (en) * 2020-12-25 2022-06-30 广东东阳光药业有限公司 Multi-substituted uracil derivatives and use thereof
WO2022135534A1 (en) * 2020-12-25 2022-06-30 广东东阳光药业有限公司 Substituted nitrogen-containing bicyclic compound and use thereof
WO2022135502A1 (en) * 2020-12-25 2022-06-30 广东东阳光药业有限公司 Multi-substituted uracil derivative and use thereof
WO2023107490A1 (en) * 2021-12-06 2023-06-15 Pretzel Therapeutics, Inc. Heterocycle-containing lonp1 inhibitor compounds, uses and methods
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
WO2023194222A1 (en) * 2022-04-05 2023-10-12 Socpra Sciences Santé Humaines S.E.C. Inhibitors of chymase for use in the selective resolution of thrombi in thrombotic or thromboembolic disorders

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403599B1 (en) * 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
US6114532A (en) 1998-02-03 2000-09-05 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, the preparation thereof, and their use as pharmaceuticals
DE19834044A1 (en) 1998-07-29 2000-02-03 Bayer Ag New substituted pyrazole derivatives
DE19834047A1 (en) 1998-07-29 2000-02-03 Bayer Ag Substituted pyrazole derivatives
US6458952B1 (en) 1999-05-19 2002-10-01 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
EP1219611A4 (en) 1999-09-03 2003-03-19 Ajinomoto Kk Novel processes for preparing oxazepine derivatives
DE19943634A1 (en) 1999-09-13 2001-04-12 Bayer Ag Novel dicarboxylic acid derivatives with pharmaceutical properties
DE19943639A1 (en) 1999-09-13 2001-03-15 Bayer Ag Dicarboxylic acid derivatives with novel pharmaceutical properties
DE19943635A1 (en) 1999-09-13 2001-03-15 Bayer Ag Novel aminodicarboxylic acid derivatives with pharmaceutical properties
DE19943636A1 (en) 1999-09-13 2001-03-15 Bayer Ag Novel dicarboxylic acid derivatives with pharmaceutical properties
GB0021315D0 (en) * 2000-08-30 2000-10-18 Dainippon Pharmaceutical Co Heterocyclic compounds and intermediates thereof
AR031176A1 (en) 2000-11-22 2003-09-10 Bayer Ag NEW DERIVATIVES OF PIRAZOLPIRIDINA SUBSTITUTED WITH PIRIDINE
DE10110749A1 (en) 2001-03-07 2002-09-12 Bayer Ag Substituted aminodicarboxylic acid derivatives
DE10110750A1 (en) 2001-03-07 2002-09-12 Bayer Ag Novel aminodicarboxylic acid derivatives with pharmaceutical properties
JP2003017508A (en) 2001-07-05 2003-01-17 Nec Corp Field effect transistor
AR038536A1 (en) 2002-02-25 2005-01-19 Upjohn Co N-ARIL-2-OXAZOLIDINONA-5- CARBOXAMIDS AND ITS DERIVATIVES
DE10220570A1 (en) 2002-05-08 2003-11-20 Bayer Ag Carbamate-substituted pyrazolopyridines
JP2003342265A (en) * 2002-05-22 2003-12-03 Senju Pharmaceut Co Ltd Triazolidine derivative and its pharmaceutical use
WO2004052858A2 (en) 2002-12-06 2004-06-24 Eli Lilly And Company Inhibitors of monoamine uptake
CN1871029A (en) * 2003-08-22 2006-11-29 帝人制药株式会社 Drug containing chymase inhibitor as the active ingredient
DE102004004928A1 (en) 2004-01-31 2005-08-18 Bayer Healthcare Ag Dibenzoxazepine II
AU2005225471B2 (en) 2004-03-26 2011-05-12 Methylgene Inc. Inhibitors of histone deacetylase
US7507748B2 (en) 2004-07-22 2009-03-24 Amgen Inc. Substituted aryl-amine derivatives and methods of use
EP1835934A4 (en) 2004-12-23 2010-07-28 Deciphera Pharmaceuticals Llc Enzyme modulators and treatments
EP1885369B1 (en) 2005-05-04 2015-09-23 Evotec AG Fused heterocyclic compounds, and compositions and uses thereof
WO2007007161A2 (en) * 2005-07-08 2007-01-18 Orchid Research Laboratories Limited Novel bio-active derivatives
EP1968950A4 (en) 2005-12-19 2010-04-28 Genentech Inc Pyrimidine kinase inhibitors
CA2642406A1 (en) 2006-02-14 2007-08-23 Pfizer Products Inc. Benzoxazinone and benzoxazepinone oxazolidinones as antibacterial agents
JO2934B1 (en) * 2006-06-23 2015-09-15 سميث كلاين بيتشام كوربوريشن Prolyl Hydroxylase Inhibitors
US7790756B2 (en) 2006-10-11 2010-09-07 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
GB0622472D0 (en) 2006-11-10 2006-12-20 Addex Pharmaceuticals Sa Novel heterocyclic derivatives
EP2114898A2 (en) 2007-02-16 2009-11-11 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
MX2009011059A (en) 2007-04-13 2009-11-26 Vertex Pharma Aminopyrimidines useful as kinase inhibitors.
WO2009049112A1 (en) 2007-10-10 2009-04-16 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
CN101827853A (en) 2007-10-19 2010-09-08 贝林格尔.英格海姆国际有限公司 Heterocycle-substituted piperazino-dihydrothienopyrimidines
WO2009135299A1 (en) * 2008-05-05 2009-11-12 Merck Frosst Canada Ltd. 3, 4 - substituted piperidine derivatives as renin inhibitors
ES2516716T3 (en) 2008-06-25 2014-10-31 Daiichi Sankyo Company, Limited Carboxylic acid compound
DE102008030091B4 (en) 2008-06-25 2011-03-03 Resprotect Gmbh Uracil derivatives and their use
UA112897C2 (en) * 2012-05-09 2016-11-10 Байєр Фарма Акцієнгезелльшафт BICYCLIC SUBSTITUTED URATILES AND THEIR APPLICATIONS FOR THE TREATMENT AND / OR PREVENTION OF DISEASES

Also Published As

Publication number Publication date
PL2847190T3 (en) 2016-12-30
HUE035462T2 (en) 2018-05-02
US9949977B2 (en) 2018-04-24
JP2017160242A (en) 2017-09-14
JP6141414B2 (en) 2017-06-07
DK2847190T3 (en) 2016-07-25
KR102083281B1 (en) 2020-05-29
CR20140513A (en) 2014-12-02
NO3045456T3 (en) 2018-03-24
US20150148340A1 (en) 2015-05-28
US20180256576A1 (en) 2018-09-13
HRP20180125T1 (en) 2018-02-23
AU2013258223B2 (en) 2017-11-09
CN104395310A (en) 2015-03-04
EA030383B1 (en) 2018-07-31
EP3045456B1 (en) 2017-10-25
EP2847190A1 (en) 2015-03-18
DOP2014000255A (en) 2015-02-27
CY1119840T1 (en) 2018-06-27
EP3045456A1 (en) 2016-07-20
UA112897C2 (en) 2016-11-10
ES2657315T3 (en) 2018-03-02
ECSP14026138A (en) 2015-12-31
CY1118900T1 (en) 2018-01-10
US10300062B2 (en) 2019-05-28
RS56784B1 (en) 2018-04-30
US20200061063A1 (en) 2020-02-27
HUE029366T2 (en) 2017-02-28
CU20140129A7 (en) 2015-02-26
EP2847190B1 (en) 2016-04-06
CN106983751B (en) 2020-01-07
MX2014013571A (en) 2014-12-08
HRP20160796T1 (en) 2016-08-12
CL2014003031A1 (en) 2015-03-06
KR20150016548A (en) 2015-02-12
EA201492040A1 (en) 2015-12-30
US20170020876A1 (en) 2017-01-26
US9481672B2 (en) 2016-11-01
MY181828A (en) 2021-01-08
CA2872906A1 (en) 2013-11-14
AU2017265047A1 (en) 2017-12-14
EA031222B1 (en) 2018-12-28
TWI579278B (en) 2017-04-21
LT3045456T (en) 2018-02-12
SI2847190T1 (en) 2016-08-31
EA201790032A1 (en) 2017-05-31
TW201406744A (en) 2014-02-16
IL253950B (en) 2019-07-31
IL235438A (en) 2017-08-31
MX357712B (en) 2018-07-20
AU2013258223A1 (en) 2014-11-27
HK1202873A1 (en) 2015-10-09
CN106983751A (en) 2017-07-28
SA113340533B1 (en) 2015-10-12
PE20142301A1 (en) 2014-12-19
JP2015516000A (en) 2015-06-04
PT3045456T (en) 2018-01-30
IL253950A0 (en) 2017-10-31
BR112014028086A2 (en) 2020-12-01
PT2847190T (en) 2016-07-14
CO7131375A2 (en) 2014-12-01
AP2014008096A0 (en) 2014-12-31
SI3045456T1 (en) 2018-03-30
CN104395310B (en) 2017-05-03
PL3045456T3 (en) 2018-03-30
CA2872906C (en) 2020-08-04
DK3045456T3 (en) 2018-01-29
US9949978B2 (en) 2018-04-24
PH12014502496A1 (en) 2015-01-12
EA030383B9 (en) 2018-12-28
TW201734007A (en) 2017-10-01
RS54901B1 (en) 2016-10-31
US20170020875A1 (en) 2017-01-26
AU2017265047B2 (en) 2019-04-18
TN2014000470A1 (en) 2016-03-30
ZA201408146B (en) 2017-01-25
JP6367421B2 (en) 2018-08-01
UY34797A (en) 2013-11-29
NZ701700A (en) 2016-09-30
MX367599B (en) 2019-08-28
WO2013167495A1 (en) 2013-11-14
JO3290B1 (en) 2018-09-16
SG10202003175QA (en) 2020-05-28
PH12014502496B1 (en) 2015-01-12
TWI635085B (en) 2018-09-11
ES2581537T3 (en) 2016-09-06

Similar Documents

Publication Publication Date Title
AR090994A1 (en) BICYCLICALLY REPLACED URACILES AND USE OF THE SAME
AR109295A1 (en) TRICYCLIC COMPOUNDS CONTAINING NITROGEN AND USES OF THE SAME IN MEDICINE
AR109805A1 (en) MICROBIOCIDES OXADIAZOL DERIVATIVES
AR093364A1 (en) IMIDAZO [1,2-A] PIRIDINCARBOXAMIDS AMINOSUSTITUIDAS AND ITS USE
AR097756A1 (en) SUBSTITUTED PHENYLALANINE DERIVATIVES
PH12015500386A1 (en) Fused bicyclic sulfamoyl derivatives and the use thereof as medicaments for the treatment of hepatitis b
AR089143A1 (en) SUBSTITUTED TRIAZOLOPIRIDINS WITH INHIBITING ACTIVITY OF TTK
EA201591703A1 (en) SUBSTITUTED 2-ABABILITIES AND THEIR APPLICATION AS OREXIN RECEPTOR MODULATORS
AR096330A1 (en) BIPIRAZOL DERIVATIVES AS JAK INHIBITORS
AR094174A1 (en) FUSIONED LACTAMAS OF ARILO AND HETEROARILO
BR112013016856A2 (en) compound, use of a compound, pharmaceutical composition and pharmaceutical
AR097754A1 (en) SUBSTITUTED DERIVATIVES OF PHENYLALANINE
EA201590023A1 (en) NEW 4-SUBSTITUTED DERIVATIVES WITH 1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-SHE, SUBSTITUTED WITH BENZIMIDAZOLES, AS ANTI-VIRUS MEANS AGAINST RESPIRATORY SYNCIAL VIRUS
AR090670A1 (en) HERBICIDE COMPOUNDS
AR097755A1 (en) SUBSTITUTED DERIVATIVES OF PHENYLALANINE AS MODULATORS OF THE XIA FACTOR
EA201390163A1 (en) HETEROBICYCLIC DERIVATIVES AS HCV INHIBITORS
AR098492A1 (en) PURINA DERIVATIVES
AR103232A1 (en) TGFbR ANTAGONISTS
AR084152A1 (en) TRIAZOLOPIRIMIDINE COMPOUNDS AS INHIBITORS OF PDE10A, A PROCESS FOR THEIR OBTAINING, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE TREATMENT OF CNS DISEASES
AR089776A1 (en) 5,8-DIHIDRO-6H-PIRAZOLO [3,4-H] QUINAZOLINAS AS IGF-1R / IR INHIBITORS
AR055344A1 (en) DERIVATIVES OF 1-OXOINDANE AND 1-OXO-2,3-DIHYDROISOINDOL AS INHIBITORS OF P38, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF DISEASES MEDIATED BY THE KINASE P38
AR093408A1 (en) DERIVATIVES OF OXAZOLIDIN-2-ONA-PYRIMIDINE
AR091185A1 (en) 1,2,4-TRIAZOL DERIVATIVES
AR093035A1 (en) PIRROLOTRIAZINONA DERIVATIVES AS PI3K INHIBITORS
AR090350A1 (en) CHEMICAL COMPOUNDS

Legal Events

Date Code Title Description
FG Grant, registration